Free tool
FAERS Monitor: Cefotan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050588 or its brand name (Cefotan, Cefotetan Disodium). Reports on generic versions are filed under their own applications.
Reports
133
Serious
109
82% of reports
Hospitalization
68
Death reported
17
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- haemolytic anaemia20
- nausea9
- renal failure9
- asthenia8
- chronic kidney disease8
- anaemia7
- dizziness7
- dyspnoea7
- hypertension7
- pain7
- urticaria7
- abdominal pain6
- anxiety6
- haemoglobin decreased6
- injury6
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 8 |
| 2006 | 13 |
| 2007 | 3 |
| 2008 | 9 |
| 2009 | 8 |
| 2010 | 7 |
| 2011 | 9 |
| 2012 | 8 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 9 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,026 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemolytic anaemiaSignal | 20 | 353.8 | 236.1 | 6,676 |
| chronic kidney diseaseSignal | 8 | 16.7 | 8.5 | 103 |
| injurySignal | 6 | 13.5 | 6.2 | 58 |
| renal failureSignal | 9 | 10.7 | 5.7 | 70 |
| haemoglobin decreasedSignal | 6 | 9.2 | 4.2 | 36 |
| urticariaSignal | 7 | 6.6 | 3.2 | 28 |
| anaemiaSignal | 7 | 5.8 | 2.8 | 23 |
| hypertensionSignal | 7 | 5.2 | 2.5 | 20 |
| abdominal painSignal | 6 | 4.1 | 1.9 | 11 |
| astheniaSignal | 8 | 3.4 | 1.7 | 11 |
| anxietySignal | 6 | 3.3 | 1.5 | 8 |
| dizziness | 7 | 2.2 | 1.1 | 4 |
| dyspnoea | 7 | 2.0 | 1.0 | 2 |
| pain | 7 | 1.8 | 0.9 | 2 |
| nausea | 9 | 1.8 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.